Allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative therapy for infants and children with many inborn errors of immunity (IEI), but adolescents and adults with IEI are rarely referred for transplant. Lack of published HSCT outcome data outside small, single-center studies and perceived high risk of transplant-related mortality have delayed the adoption of HSCT for IEI patients presenting or developing significant organ damage later in life. This large retrospective, multicenter HSCT outcome study reports on 329 IEI patients (age range, 15-62.5 years at HSCT). Patients underwent first HSCT between 2000 and 2019. Primary endpoints were overall survival (OS) and event-free survival (EFS). We also evaluated the influence of IEI-subgroup and IEI-specific risk factors at HSCT, including infections, bronchiectasis, colitis, malignancy, inflammatory lung disease, splenectomy, hepatic dysfunction, and systemic immunosuppression. At a median follow-up of 44.3 months, the estimated OS at 1 and 5 years post-HSCT for all patients was 78% and 71%, and EFS was 65% and 62%, respectively, with low rates of severe acute (8%) or extensive chronic (7%) graft-versus-host disease. On univariate analysis, OS and EFS were inferior in patients with primary antibody deficiency, bronchiectasis, prior splenectomy, hepatic comorbidity, and higher hematopoietic cell transplant comorbidity index scores. On multivariable analysis, EFS was inferior in those with a higher number of IEI-associated complications. Neither age nor donor had a significant effect on OS or EFS. We have identified age-independent risk factors for adverse outcome, providing much needed evidence to identify which patients are most likely to benefit from HSCT.

  • This is the largest cohort of transplanted adolescent and adult IEI patients studied to date, detailing outcomes for 329 patients.

  • This study demonstrates OS and EFS and identifies adverse risk factors to help identify patients most likely to benefit from HSCT.

1.
Tangye
SG
,
Al-Herz
W
,
Bousfiha
A
, et al
.
The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS Committee
.
J Clin Immunol
.
2021
;
41
(
3
):
666
-
679
.
2.
Lankester
AC
,
Neven
B
,
Mahlaoui
N
, et al
.
Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort
.
J Allergy Clin Immunol
.
2022
;
149
(
5
):
1744
-
1754.e8
.
3.
Ferrua
F
,
Galimberti
S
,
Courteille
V
, et al
.
Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study
.
J Allergy Clin Immunol
.
2019
;
143
(
6
):
2238
-
2253
.
4.
Chiesa
R
,
Wang
J
,
Blok
HJ
, et al
.
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
.
Blood
.
2020
;
136
(
10
):
1201
-
1211
.
5.
Burroughs
LM
,
Petrovic
A
,
Brazauskas
R
, et al
.
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
.
Blood
.
2020
;
135
(
23
):
2094
-
2105
.
6.
Passweg
JR
,
Baldomero
H
,
Chabannon
C
, et al
.
The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
.
Bone Marrow Transplant
.
2020
;
55
(
8
):
1604
-
1613
.
7.
Morris
EC
.
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
.
Hematol Am Soc Hematol Educ Program
.
2020
;
2020
:
649
-
660
.
8.
Marsh
RA
,
Leiding
JW
,
Logan
BR
, et al
.
Chronic Granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT
.
J Clin Immunol
.
2019
;
39
(
7
):
653
-
667
.
9.
Burns
SO
,
Morris
EC
.
How I use allogeneic HSCT for adults with inborn errors of immunity
.
Blood
.
2021
;
138
(
18
):
1666
-
1676
.
10.
Wehr
C
,
Gennery
AR
,
Lindemans
C
, et al
.
Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency
.
J Allergy Clin Immunol
.
2015
;
135
(
4
):
988
-
997
.
11.
Albert
MH
,
Hauck
F
,
Wiebking
V
, et al
.
Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies
.
J Allergy Clin Immunol Pract
.
2018
;
6
(
1
):
298
-
301.e2
.
12.
Fox
TA
,
Chakraverty
R
,
Burns
S
, et al
.
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
.
Blood
.
2018
;
131
(
8
):
917
-
931
.
13.
Dimitrova
D
,
Gea-Banacloche
J
,
Steinberg
SM
, et al
.
Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases
.
Biol Blood Marrow Transplant
.
2020
;
26
(
1
):
94
-
106
.
14.
Duarte
RF
,
Labopin
M
,
Bader
P
, et al
.
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
.
Bone Marrow Transplant
.
2019
;
54
(
10
):
1525
-
1552
.
15.
Kanate
AS
,
Majhail
NS
,
Savani
BN
, et al
.
Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy
.
Biol Blood Marrow Transplant
.
2020
;
26
(
7
):
1247
-
1256
.
16.
Lankester
AC
,
Albert
MH
,
Booth
C
, et al
.
EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity
.
Bone Marrow Transplant
.
2021
;
56
(
9
):
2052
-
2062
.
17.
Filipovich
AH
,
Weisdorf
D
,
Pavletic
S
, et al
.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
.
Biol Blood Marrow Transplant
.
2005
;
11
(
12
):
945
-
956
.
18.
Rosenberg
E
,
Dent
PB
,
Denburg
JA
.
Primary immune deficiencies in the adult: a previously underrecognized common condition
.
J Allergy Clin Immunol Pract
.
2016
;
4
(
6
):
1101
-
1107
.
19.
Morris
EC
,
Albert
MH
.
Allogeneic HSCT in adolescents and young adults with primary immunodeficiencies
.
Front Pediatr
.
2019
;
7
:
437
.
20.
Thakar
MS
,
Broglie
L
,
Logan
B
, et al
.
The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases
.
Blood
.
2019
;
133
(
7
):
754
-
762
.
21.
Sorror
M
,
Storer
B
,
Sandmaier
BM
, et al
.
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
.
Cancer
.
2008
;
112
(
9
):
1992
-
2001
.
22.
Valcárcel
D
,
Sureda
A
. Graft failure. In:
Carreras
E
,
Dufour
C
,
Mohty
M
,
Kröger
N
, eds.
The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies
.7th ed..
Cham, Switzerland
:
Springer
;
2018
:
307
-
315
.
23.
Güngör
T
,
Teira
P
,
Slatter
M
, et al
.
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study
.
Lancet
.
2014
;
383
(
9915
):
436
-
448
.
24.
Albert
MH
,
Bittner
TC
,
Nonoyama
S
, et al
.
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options
.
Blood
.
2010
;
115
(
16
):
3231
-
3238
.
25.
Acevedo
MJ
,
Wilder
JS
,
Adams
S
, et al
.
Outcomes of related and unrelated donor searches among patients with primary immunodeficiency diseases referred for allogeneic hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2019
;
25
(
8
):
1666
-
1673
.
26.
Luu
S
,
Spelman
D
,
Woolley
IJ
.
Post-splenectomy sepsis: preventative strategies, challenges, and solutions
.
Infect Drug Resist
.
2019
;
12
:
2839
-
2851
.
27.
Resnick
ES
,
Moshier
EL
,
Godbold
JH
,
Cunningham-Rundles
C
.
Morbidity and mortality in common variable immune deficiency over 4 decades
.
Blood
.
2012
;
119
(
7
):
1650
-
1657
.
28.
Gathmann
B
,
Mahlaoui
N
,
Gérard
L
, et al
.
Clinical picture and treatment of 2212 patients with common variable immunodeficiency
.
J Allergy Clin Immunol
.
2014
;
134
(
1
):
116
-
126
.
29.
Edwards
ESJ
,
Bosco
JJ
,
Aui
PM
, et al
.
Predominantly antibody-deficient patients with non-infectious complications have reduced naive B, Treg, Th17, and Tfh17 Cells
.
Front Immunol
.
2019
;
10
:
2593
.
30.
Shah
AJ
,
Sokolic
R
,
Logan
B
, et al
.
Quality of life of patients with Wiskott Aldrich syndrome and X-linked thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation
.
J Clin Immunol
.
2019
;
39
(
8
):
786
-
794
.
31.
Pulvirenti
F
,
Sangerardi
M
,
Plebani
A
, et al
.
Health-related quality of life and emotional difficulties in chronic granulomatous disease: Data on adult and pediatric patients from Italian Network for Primary Immunodeficiency (IPINet)
.
J Clin Immunol
.
2020
;
40
(
2
):
289
-
298
.
You do not currently have access to this content.

Sign in via your Institution